Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Recovery -11% primary Improvement Relative Risk Recovery (b) -87% Viral load 5% c19nitazoxanide.com Fowotade et al. NCT04459286 Nitazoxanide RCT LATE Favors nitazoxanide Favors control
Fowotade, 57 patient nitazoxanide late treatment RCT: 11% worse recovery [p=0.73] and 5% improved viral clearance [p=0.92] https://c19p.org/fowotade
copied to clipboard
Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19
Fowotade et al., medRxiv, doi:10.1101/2022.02.03.22270152 (Preprint), NCT04459286 (history)
4 Feb 2022    Source   PDF   Share   Tweet
Small RCT in Nigeria with 31 nitazoxanide and atazanavir/ritonavir patients, and 26 control patients, showing no significant differences with treatment. 4 treatment group patients discontinued treatment due to the size of the tablets. Time from onset is not provided, only time from diagnosis. NACOVID. 14-day course of nitazoxanide (1000 mg b.i.d.) and atazanavir/ritonavir (300/100 mg od). NCT04459286 (history).
risk of no recovery, 11.4% higher, HR 1.11, p = 0.72, treatment 31, control 26, inverted to make RR<1 favor treatment, time to clinical improvement, Cox proportional hazards, primary outcome.
risk of no recovery, 86.9% higher, HR 1.87, p = 0.10, treatment 31, control 26, inverted to make RR<1 favor treatment, time to symptom resolution, Cox proportional hazards.
viral load, 5.2% lower, relative load 0.95, p = 0.92, treatment 31, control 26, viral load change from days 2 to 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fowotade et al., 4 Feb 2022, Randomized Controlled Trial, Nigeria, preprint, 18 authors, study period 25 November, 2020 - 20 April, 2021, this trial uses multiple treatments in the treatment arm (combined with atazanavir/ritonavir) - results of individual treatments may vary, trial NCT04459286 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperNitazoxanideAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit